FDA Grants Orphan Drug Designation to Cognetix' Investigational CGX-1160 for the Treatment of Chronic Intractable Pain
Posted on: Tuesday, 30 August 2005, 09:01 CDT
Cognetix Inc., a biotechnology company focused on the development of drugs for chronic intractable pain, today announced that the U.S. Food and Drug Administration (FDA) has granted an Orphan Drug designation to Cognetix lead compound CGX-1160 for the intrathecal treatment of neuropathic pain associated with spinal cord injury. CGX 1160 has completed a Phase 1b clinical trial for the treatment of chronic, intractable pain at Brigham and Womens Hospital in Boston.
About FDA Orphan Drug Designation
Products designated as orphan drugs are those that are being developed to treat diseases affecting fewer than 200,000 people in the United States. The Orphan Drug Act guarantees seven years of market exclusivity to the first sponsor that obtains market approval for an orphan-designated product. Additional incentives for the sponsor include tax credits related to clinical trial expenses and a waiver from the FDA user fee for review of an application for the indication designated.
Cognetix' Clinical Development Program
Cognetix lead compound, CGX-1160 is based on a novel peptide synthesized from marine cone snails. Safety margins observed in the Phase 1b clinical trial at Brigham and Womens are consistent with the Company's extensive pre-clinical data demonstrating that CGX-1160 is a broad spectrum non-opioid analgesic with a wide safety margin. As such, CGX-1160 could provide physicians and patients with the "next generation" of conopeptide-based analgesics that have been designed to address safety considerations, such as narrow therapeutic index, inherent in first-generation conopeptides for pain management.
About Cognetix
Cognetix has demonstrated that conopeptides represent a large and diverse pharmacopoeia of bioactive molecules with subtype selective activity at many molecular targets of interest in CNS pharmaceutical drug development.
Cognetix synthesizes peptides from cone snails and leverages these potent compounds to create a variety of therapeutics including non-narcotic pain medications and other CNS therapeutics.
The Company's drug discovery program is powered by a platform consisting of the world's most extensive conopeptide data base. The Company's patent portfolio on conopeptide sequences, uses, synthesis and methods consists of 80 issued or allowed U.S. and international patents and an additional 80 patents pending.
Source: Business Wire
Related Articles
- Considering Usual Medical Care In Clinical Trial Design
- Perceptive Informatics Survey Results Reveal Top Barriers to Implementing Adaptive Trial Designs
- AZX100 Pre-Clinical Results Show Reduction of Fibrosis and Scarring; Human Clinical Safety Trials Continuing
- Sciele Pharma Completes Phase III Safety Trial for Glycopyrrolate Liquid, a Treatment for Chronic, Moderate-to-Severe Drooling in Pediatric Patients
- Sciele Pharma Completes Patient Enrollment for Pivotal Phase III Safety Trial for Glycopyrrolate
- Abbott Enrolls First Patient in World's First Clinical Trial Designed to Study Drug Eluting Stent Treatment in Women
- Sciele Pharma Begins Pivotal Phase III Safety Trial for Glycopyrrolate
- The Burgeoning Use of Surrogate End Points Creates a Significant Need to Identify New Biomarkers - Challenges in Oncology Clinical Trial Design
- Extensive Post-License Data Reaffirm Clinical Safety Profile of Prolastin(R)
- Cognetix Announces Mechanism of Action for Its Lead Compound -- CGX-1160 -- To Treat Chronic Intractable Pain
 |
 |
User Comments (0)
RSS Feeds